The listing on one of the world’s largest global cryptocurrency exchanges expands market access and secondary liquidity for Enlivex’s primary digital treasury asset Nes-Ziona, Israel, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, “Enlivex” or “the Company”) today reported that its treasury asset, the RAIN token, has been listed on the KuCoin cryptocurrency exchange effective January 6, 2026, expanding access to the token across a major global digital asset trading platform. KuC ...

Toronto, Ontario--(Newsfile Corp. - December 29, 2025) - Pineapple Financial Inc. (NYSE American: PAPL) ("Pineapple" or "the Company"), a leading fintech platform, today announced the appointment of Anthony Georgiades, General Partner at Innovating Capital, to its Board of Directors. Mr. Georgiades will also serve on Pineapple's newly formed Special Advisory Committee, which will oversee the Company's digital asset treasury strategy focused on accumulating Injective ($INJ) tokens.As a member of the Special ...

Core Insights - Enlivex Therapeutics Ltd. will host a virtual fireside chat on December 11, 2025, to discuss its recent $212 million private placement and future plans [1][2][3] - The company is focusing on advancing the clinical development of Allocetra™, a therapy for osteoarthritis, which affects over 32.5 million Americans and 300 million people globally [5] Company Plans - Shai Novik, Executive Chairman, will provide updates on the digital asset treasury strategy centered around RAIN token accumulation [2] - Enlivex aims to offer investors exposure to RAIN as a primary treasury reserve asset [4] Clinical Development - Allocetra™ is designed to treat osteoarthritis, a prevalent joint disease with significant hospitalization rates in the U.S. [5] - There are currently no FDA or EMA approved medications that can halt or reverse joint damage in osteoarthritis patients [5]

Core Insights - mF International Limited has successfully closed a private placement, raising $500 million through the issuance of 50 million Class A ordinary shares and pre-funded warrants at a price of $10.00 each [1][3][8] Group 1: Financial Details - The net proceeds from the private placement will primarily be used to advance the Company's digital asset treasury strategy, including the acquisition of Bitcoin Cash (BCH) and other cryptocurrencies, with remaining funds allocated to general corporate purposes [2][4] - The capital raised enhances the Company's financial flexibility to execute a disciplined digital asset treasury strategy focused on optimizing returns and managing risk [3][4] Group 2: Company Overview - mF International Limited is a British Virgin Islands holding company with three operating subsidiaries in Hong Kong, primarily engaged in providing financial trading solutions via SaaS [4] - The Company plans to initiate a digital asset treasury strategy that includes investments in BCH and other digital assets [4]

Core Insights - Enlivex has implemented the world's first RAIN prediction markets token digital asset treasury strategy through RAIN token accumulation [1][3][7] - The company is focused on the clinical development of Allocetra, a novel therapy for knee osteoarthritis, addressing a significant unmet medical need in a growing market [2][8] Company Developments - Enlivex has closed a $212 million private investment, with plans to utilize the proceeds for the RAIN prediction markets token treasury strategy while maintaining its core business operations [3][7] - Former Italian Prime Minister Matteo Renzi has joined the Board of Directors, emphasizing the importance of responsible innovation and the potential of blockchain technologies [5] RAIN Protocol Overview - RAIN is a decentralized predictions and options protocol built on the Arbitrum network, allowing users to create and trade custom options on various markets [4] - The protocol features a deflationary Buyback & Burn mechanism and aims to be a leading platform for prediction markets, promoting transparency and community participation [4] Market Context - Osteoarthritis affects over 32.5 million Americans and more than 300 million people globally, with a projected increase to 78 million Americans by 2040 [8] - There are currently no FDA or EMA approved medications that can effectively halt or reverse the progression of joint damage in osteoarthritis patients, highlighting a critical need for effective treatments [8]

Core Insights - IP Strategy is the first Nasdaq-listed company to operate a digital asset treasury strategy centered on the $IP token, providing investors with exposure to the programmable intellectual property economy valued at $80 trillion [3] - The company held its inaugural Investor Day 2025, where it discussed its growth strategy and the convergence of AI, blockchain, and intellectual property [2][3] - Story, the blockchain network supporting the $IP token, has received $136 million in backing and launched its mainnet in February 2025, enabling the monetization of intellectual property in real time [5] Company Overview - IP Strategy operates a revenue-generating validator for the Story network and holds $IP tokens as a primary reserve asset [3] - The company aims to provide public market investors with a regulated equity format to participate in the Story ecosystem, which facilitates on-chain registration, licensing, and monetization of intellectual property [3] Industry Context - The Story network is described as an AI-native blockchain that makes intellectual property programmable and traceable, allowing creators to turn various forms of content into legally enforceable digital assets [5] - The convergence of AI, blockchain, and intellectual property is seen as a significant trend shaping a new investable asset class [2]

Table of Contents As filed with the Securities and Exchange Commission on October 29, 2025. Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) 50 Health Sciences Drive Stony Brook, New York 11 ...

Core Insights - Qualigen Therapeutics Inc. has announced a strategic partnership with BitGo to support its C10 treasury strategy, which aims to accumulate a market-cap-weighted basket of the world's top 10 crypto assets, excluding stablecoins [1][4]. Group 1: Partnership Details - The partnership will allow Qualigen to utilize BitGo's comprehensive treasury management services, which include access to deep liquidity and secure custody solutions [2][3]. - BitGo's OTC desk will facilitate efficient investments across a diversified basket of 10 digital assets, marking a significant advancement in Qualigen's treasury strategy [2][4]. Group 2: Security and Compliance - Qualigen's treasury assets will be stored securely in regulated cold storage by BitGo, adhering to high security standards and compliance protocols [3][4]. - BitGo's expertise in digital assets will simplify the complexities associated with institutional digital asset adoption, enabling Qualigen to focus on sustainable growth and digital integration [3][4]. Group 3: Strategic Vision - The partnership reflects Qualigen's commitment to financial resilience and leadership in the evolving digital economy, as stated by Co-CEO Jerry Wang [4]. - The $30 million multi-asset allocation signifies growing enterprise confidence in adopting a digital-first treasury strategy [4].

Core Viewpoint - Cemtrex Inc. has initiated a digital asset treasury strategy by acquiring approximately $1 million worth of Solana (SOL) and aims to expand its crypto reserves to $10 million over time [1][2]. Group 1: Acquisition and Strategy - The company purchased 5,500 SOL at an average cost of approximately $181 per token, with plans to stake its position for on-chain yield and operate its own validator node [2]. - Cemtrex's long-term goal is to build a $10 million reserve position across strategic crypto networks, with Solana as the foundational asset [2][4]. Group 2: Solana's Performance and Positioning - Solana is currently processing over 1,000 transactions per second and handled more than 90 billion transactions in June 2025, outperforming all other layer-one and layer-two blockchains combined [3]. - The blockchain features a burn mechanism tied to usage and a hardcoded inflation schedule that will bottom out at 1.5% by 2028, positioning it as a foundational layer for digital trust and settlement [3]. Group 3: Long-term Vision - The acquisition is described as a long-duration bet on Solana, which is viewed as the most capable and capital-efficient blockchain system, expected to compound its network advantage faster than the market anticipates [4][5]. - Cemtrex is exploring the integration of blockchain technologies into its product lines, including cryptographic video authentication and decentralized timestamping through its subsidiary, Vicon [4].

Core Viewpoint - Liminatus Pharma, Inc. has engaged Digital Offering LLC as its exclusive placement agent to explore innovative treasury-backed financing options to strengthen its capital structure [1][2][4] Group 1: Engagement and Strategy - The engagement with Digital Offering supports Liminatus's review of a digital asset treasury strategy, evaluating modern financial tools for capital structure enhancement [2][4] - The potential funding initiative may involve various exempt financing structures, including convertible debentures and equity-linked securities, compliant with U.S. securities laws [2][4] Group 2: Role of Digital Offering - Digital Offering is tasked with sourcing institutional and digital asset-focused investors and structuring a compliant financing solution for Liminatus [3][4] - The partnership aims to explore strategic funding opportunities in both traditional markets and the evolving digital asset landscape [4] Group 3: Company Overview - Liminatus is a preclinical-stage biopharmaceutical company focused on developing targeted cancer immunotherapies, advancing a pipeline of novel therapies [6] - The company is committed to responsible innovation in its capital strategy to support long-term scientific and operational objectives [6]